Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study
Author(s) -
Douglas Tremblay,
Maaike van Gerwen,
Mathilda Alsen,
Santiago Thibaud,
Alaina J. Kessler,
Sangeetha Venugopal,
Iman Makki,
Qian Qin,
Sirish Dharmapuri,
Tomi Jun,
Sheena Bhalla,
Shana Berwick,
Jonathan Feld,
John Mascarenhas,
Kevin Troy,
Caroline Cromwell,
Andrew Dunn,
William Oh,
Leonard Naymagon
Publication year - 2020
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2020006941
Subject(s) - propensity score matching , medicine , observational study , retrospective cohort study , covid-19 , comorbidity , cohort study , intensive care medicine , medline , cohort , disease , political science , infectious disease (medical specialty) , law
Tremblay and colleagues asked whether patients receiving either routine anticoagulation or antiplatelet therapy for existing conditions prior to becoming ill with COVID-19 have different outcomes from patients receiving neither therapy. After matching for existing comorbidities, this retrospective observational study finds no evidence for an effect of prediagnosis anticoagulation on mortality.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom